TARS
Tarsus Pharmaceuticals, Inc. NASDAQ Listed Oct 16, 2020$64.76
After hrs
$63.68
-1.67%
Mkt Cap $2.8B
52w Low $38.51
56.2% of range
52w High $85.25
50d MA $68.80
200d MA $66.33
P/E (TTM)
-40.0x
EV/EBITDA
-62.1x
P/B
7.7x
Debt/Equity
0.3x
ROE
-19.3%
P/FCF
-153.4x
RSI (14)
—
ATR (14)
—
Beta
0.63
50d MA
$68.80
200d MA
$66.33
Avg Volume
570.6K
About
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is als…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | AMC | -0.10 | -0.20 | -94.2% | 69.59 | +7.1% | +7.8% | +4.4% | +9.0% | +8.5% | +11.3% | — |
| Nov 4, 2025 | AMC | -0.35 | -0.30 | +14.3% | 71.50 | -4.2% | -4.6% | -4.8% | -4.5% | +1.8% | +5.8% | — |
| Aug 6, 2025 | AMC | -0.33 | -0.48 | -45.5% | 41.64 | +8.0% | +15.2% | +14.9% | +20.2% | +23.3% | +26.6% | — |
| May 1, 2025 | AMC | -0.69 | -0.64 | +7.2% | 50.30 | -2.8% | -5.8% | -4.6% | -7.7% | -5.9% | -6.3% | — |
| Feb 25, 2025 | AMC | -0.68 | -0.60 | +11.8% | 41.29 | +2.6% | +3.1% | +5.5% | +7.7% | +3.5% | +7.8% | — |
| Nov 13, 2024 | AMC | -0.94 | -0.61 | +35.1% | 46.51 | +9.7% | +0.3% | -3.6% | -4.0% | +0.8% | +0.2% | — |
| Aug 8, 2024 | AMC | -0.98 | -0.88 | +10.2% | 23.61 | +14.4% | +13.7% | +11.0% | +12.0% | +12.9% | +14.2% | — |
| May 8, 2024 | AMC | -1.15 | -1.01 | +12.2% | 37.35 | +13.8% | -8.9% | -0.9% | +2.7% | +1.7% | +3.1% | — |
| Feb 27, 2024 | AMC | -1.37 | -1.31 | +4.4% | 39.22 | +3.0% | -3.4% | -2.5% | -5.8% | -5.9% | -8.8% | — |
| Nov 9, 2023 | AMC | -1.40 | -1.28 | +8.6% | 15.57 | +9.6% | +12.2% | +10.3% | +15.1% | +15.2% | +13.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Oppenheimer | Reiterates | Outperform | $98 | $60.97 | $61.07 | +0.2% | +0.8% | -0.1% | +1.8% | -0.5% | +4.3% |
| Feb 25 | Guggenheim | Maintains | Buy → Buy | — | $75.01 | $74.97 | -0.1% | -3.1% | +1.1% | +0.7% | +3.2% | +2.1% |
| Feb 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $75.01 | $74.97 | -0.1% | -3.1% | +1.1% | +0.7% | +3.2% | +2.1% |
| Nov 5 | Guggenheim | Maintains | Buy → Buy | — | $71.50 | $68.50 | -4.2% | -4.6% | -4.8% | -4.5% | +1.8% | +5.8% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $72.93 | $73.99 | +1.5% | -2.4% | -2.9% | -5.8% | -6.3% | -9.4% |
| May 5 | Goldman Sachs | Maintains | Neutral → Neutral | — | $47.36 | $46.95 | -0.9% | +1.4% | -1.9% | -0.0% | -0.5% | -5.5% |
| May 2 | Guggenheim | Maintains | Buy → Buy | — | $50.30 | $48.89 | -2.8% | -5.8% | -4.6% | -7.7% | -5.9% | -6.3% |
| Mar 6 | Jefferies | Maintains | Buy → Buy | — | $44.54 | $43.80 | -1.7% | -2.2% | +4.3% | +0.1% | +5.9% | +5.7% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.29 | $42.35 | +2.6% | +3.1% | +5.5% | +7.7% | +3.5% | +7.8% |
| Feb 26 | Guggenheim | Maintains | Buy → Buy | — | $41.29 | $42.35 | +2.6% | +3.1% | +5.5% | +7.7% | +3.5% | +7.8% |
Recent Filings
8-K
Tarsus Pharmaceuticals, Inc. -- 8-K Filing
Tarsus Pharmaceuticals nearly tripled XDEMVY sales to $451.4 million in 2025, projects over $2 billion peak sales potential, and advances pipeline candidates TP-04 and TP-05 into Phase 2 trials.
Feb 23
8-K · 5.02
!!! Very High
Tarsus Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Tarsus Pharmaceuticals appointed David E.I. Pyott as a Class III director, adding experienced leadership to its board governance.
Feb 18
Data updated apr 27, 2026 3:59am
· Source: massive.com